Interferon-α effects are exaggerated when administered on a psychosocial stressor backdrop: Cytokine, corticosterone and brain monoamine variations

Journal of Neuroimmunology

Volumn 186, Issue 1-2, 2007, Pages 45-53

  Anisman, Hymie ^a,b   Poulter, Michael O ^c   Gandhi, Reno ^a   Merali, Zul ^b   Hayley, Shawn ^a  

^a CARLETON UNIVERSITY   (Canada)

^b ROYAL OTTAWA HOSPITAL   (Canada)

^c ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

Cortisol; Cytokine; Depression; Interferon; Monoamine; Stress

Indexed keywords

ALPHA INTERFERON; BRAIN MONOAMINE; CORTICOSTERONE; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; NORADRENALIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; DOSE RESPONSE; DRUG DOSE COMPARISON; HIPPOCAMPUS; ILLNESS BEHAVIOR; IMMUNOTHERAPY; MALE; MENTAL STRESS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SOCIAL ISOLATION;

ANALYSIS OF VARIANCE; ANIMALS; BIOGENIC MONOAMINES; BIOLOGICAL RESPONSE MODIFIERS; BRAIN; BRAIN CHEMISTRY; CORTICOSTERONE; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; INTERFERON-ALPHA; MICE; RADIOIMMUNOASSAY; STRESS, PSYCHOLOGICAL;

EID: 34248679889     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2007.02.008     Document Type: Article

References (59)

1. Abe S., Hori T., Suzuki T., Baba A., Shiraishi H., and Yamamoto T. Effects of chronic administration of interferon alpha A/D on serotonergic receptors in rat brain. Neurochem. Res. 24 (1999) 359-363
2. Anisman H., and Merali Z. Anhedonic and anxiogenic effects of cytokine exposure. Adv. Exp. Med. Biol. 461 (1999) 199-233
3. Anisman H., and Merali Z. Cytokines, stress and depressive illness: brain-immune interactions. Ann. Med. 35 (2003) 2-11
4. Anisman H., Ravindran A.V., Griffiths J., and Merali Z. Endocrine and cytokine correlates of major depression and dysthymia with typical or atypical features. Mol. Psychiatry 4 (1999) 182-188
5. Anisman H., Merali Z., and Hayley S. Depressive Disorders: Contribution of Cytokines and other Growth Factors. In: Hersen M., and Gross A.M. (Eds). Handbook of Clinical Psychology (2007), Wiley
6. Arango V., Huang Y.Y., Underwood M.D., and Mann J.J. Genetics of the serotonergic system in suicidal behavior. J. Psychiat. Res. 37 (2003) 375-386
7. Avitsur R., Padgett D.A., and Sheridan J.F. Social interactions, stress, and immunity. Neurol. Clin. 24 (2006) 483-491
8. Basterzi A.D., Aydemir C., Kisa C., Aksaray S., Tuzer V., Yazici K., and Goka E. IL-6 levels decrease with SSRI treatment in patients with major depression. Hum. Psychopharmacol. 20 (2005) 473-476
9. Bonaccorso S., Puzella A., Marino V., Pasquini M., Biondi M., Artini, et al. Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms. Psychiatry Res. 105 (2001) 45-55
10. Bonaccorso S., Puzella A., Marino V., Pasquini M., Biondi M., Artini, et al. Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. J. Clin. Psychopharmacol. 22 (2002) 86-90
11. Capuron L., and Miller A.H. Cytokines and psychopathology: lessons from interferon-alpha. Biol. Psychiatry 56 (2004) 819-824
12. Capuron L., Gumnick J.F., Musselman D.L., Lawson D.H., Reemsnyder A., Nemeroff C.B., and Miller A.H. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 26 (2002) 643-652
13. Capuron L., Ravaud A., Neveu P.J., Miller A.H., Maes M., and Dantzer R. Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol. Psychiatry 7 (2002) 468-473
14. Cassidy E.M., Manning D., Byrne S., Bolger E., Murray F., Sharifi N., et al. Acute effects of low-dose interferon-alpha on serum cortisol and plasma interleukin-6. J. Psychopharmacol. 16 (2002) 230-234
15. Cotler S.J., Reddy K.R., McCone J., Wolfe D.L., Liu A., Craft T.R., et al. An analysis of acute changes in interleukin-6 levels after treatment of hepatitis C with consensus interferon. J. Interferon Cytokine Res. 21 (2001) 1011-1019
16. De La Garza II R., and Asnis G.M. The non-steroidal anti-inflammatory drug diclofenac sodium attenuates IFN-alpha induced alterations to monoamine turnover in prefrontal cortex and hippocampus. Brain Res. 977 (2003) 70-79
17. De La Garza II R., Asnis G.M., Pedrosa E., Stearns C., Migdal A.L., Reinus J.F., et al. Recombinant human interferon-alpha does not alter reward behavior, or neuroimmune and neuroendocrine activation in rats. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 29 (2005) 781-792
18. Dieperink E., Ho S.B., Thuras P., and Willenbring M.L. A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics 44 (2003) 104-112
19. Franklin K.B.J., and Paxinos G. A Stereotaxic Atlas of the Mouse Brain (1997), Academic Press, New York
20. Frodl T., Schaub A., Banac S., Charypar M., Jager M., Kummler P., et al. Reduced hippocampal volume correlates with executive dysfunctioning in major depression. J. Psychiatry Neurosci. 31 (2006) 316-323
21. Gandhi, R., Hayley, S., Gibb, J., Merali, Z. and Anisman, H in press. Influence of Poly I:C on sickness behaviors, plasma cytokines, corticosterone and central monoamine activity: moderation by social stressors. Brain Behav. Immun.
22. Gisslinger H., Svoboda T., Clodi M., Gilly B., Ludwig H., Havelec L., and Luger A. Interferon-alpha stimulates the hypothalamic-pituitary-adrenal axis in vivo and in vitro. Neuroendocrinology 57 (1993) 489-495
23. Hauser P., Khosla J., Aurora H., Laurin J., Kling M.A., Hill J., et al. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol. Psychiatry 7 (2002) 942-947
24. Hayley S., Brebner K., Lacosta S., Merali Z., and Anisman H. Sensitization to the effects of tumor necrosis factor-α: neuroendocrine, central monoamine and behavioral variations. J. Neurosci. 19 (1999) 5654-5665
25. Hayley S., Poulter M., Merali Z., and Anisman H. The pathogenesis of clinical depression: stressor- and cytokine-induced alterations of neuroplasticity. Neuroscience 135 (2005) 659-678
26. Kamata M., Higuchi H., Yoshimoto M., Yoshida K., and Shimizu T. Effect of single intracerebroventricular injection of alpha-interferon on monoamine concentrations in the rat brain. Eur. Neuropsychopharmacol. 10 (2000) 129-132
27. Kaneko N., Kudo K., Mabuchi T., Takemoto K., Fujimaki K., Wati H., et al. Suppression of cell proliferation by interferon-alpha through interleukin-1 production in adult rat dentate gyrus. Neuropsychopharmacology (2006) 2619-2626
28. Kentner A.C., James J.S., Miguelez M., and Bialajew C. Investigating the hedonic effects of interferon-alpha on female rats using brain-stimulation reward. Behav. Brain Res. 177 (2007) 90-99
29. Kraus M.R., Schafer A., Faller H., Csef H., and Scheurlen M. Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C. Aliment. Pharmacol. Ther. 16 (2002) 1091-1099
30. Larson S.J., Romanoff R.L., Dunn A.J., and Glowa J.R. Effects of interleukin-1 beta on food-maintained behavior in the mouse. Brain Behav. Immun. 16 (2002) 398-410
31. Loftis J.M., and Hauser P. The phenomenology and treatment of interferon-induced depression. J. Affect. Disord. 82 (2004) 175-190
32. Loftis J.M., Wall J.M., Pagel R.L., and Hauser P. Administration of pegylated interferon-alpha-2a or -2b does not induce sickness behavior in Lewis rats. Psychoneuroendocrinology 31 (2006) 1289-1294
33. Maes M. Evidence for an immune response in major depression: a review and hypothesis. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 19 (1995) 11-38
34. Maes M. Major depression and activation of the inflammatory response system. Adv. Exp. Med. Biol. 461 (1999) 25-45
35. Menkes D.B., and MacDonald J.A. Interferons, serotonin and neurotoxicity. Psychol. Med. 30 (2000) 259-268
36. Menzies R., Phelps C., Wiranowska M., Oliver J., Chen L., Horvath E., and Hall N. The effect of interferon-alpha on the pituitary-adrenal axis. J. Interferon Cytokine Res. 16 (1996) 619-629
37. Merali Z., Brennan K., Brau P., and Anisman H. Dissociating anorexia and anhedonia elicited by interleukin-1β: antidepressant and gender effects on responding for "free chow" and "earned" sucrose intake. Psychopharmacology 165 (2002) 413-418
38. Merali Z., Brennan K., Brau P., and Anisman H. Dissociating anorexia and anhedonia elicited by interleukin-1β: antidepressant and gender effects on responding for "free chow" and "earned" sucrose intake. Psychopharmacology 165 (2003) 413-418
39. Miyaoka H., Otsubo T., Kamijima K., Ishii M., Onuki M., and Mitamura K. Depression from interferon therapy in patients with hepatitis C. Am. J. Psychiatr. 156 (1999) 1120
40. Morikawa O., Sakai N., Obara H., and Saito N. Effects of interferon-alpha, interferon-gamma and cAMP on the transcriptional regulation of the serotonin transporter. Eur. J. Pharmacol. 349 (1998) 317-324
41. Mullar N., and Ackenheil M. Psychoneuroimmunology and the cytokine action in the CNS: implications for psychiatric disorders. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 22 (1998) 1-33
42. Musselman D.L., Lawson D.H., Gumnick J.F., Manatunga A., Penna S., Goodkin R., et al. Paroxetine for the prevention of the depression and neurotoxicity induced by high dose interferon alpha. New Engl. J. Med 344 (2001) 961-966
43. Pandey G.N., Dwivedi Y., Rizavi H.S., Ren X., Pandey S.C., Pesold C., et al. Higher expression of serotonin 5-HT(2A) receptors in the postmortem brains of teenage suicide victims. Am. J. Psychiatr. 159 (2002) 419-429
44. Raison C.L., Demetrashvili M., Capuron L., and Miller A.H. Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs 19 (2005) 105-123
45. Raison C.L., Capuron L., and Miller A.H. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 27 (2006) 24-31
46. Reichenberg A., Yirmiya R., Schuld A., Kraus T., Haack M., Morag A., and Pollmacher T. Cytokine-associated emotional and cognitive disturbances in humans. Arch. Gen. Psychiatry 58 (2001) 445-452
47. Russo S., Kema I.P., Haagsma E.B., Boon J.C., Willemse P.H., den Boer J.A., et al. Irritability rather than depression during interferon treatment is linked to increased tryptophan catabolism. Psychosom. Med. 67 (2005) 773-777
48. Saphier D., Roerig S.C., Ito C., Vlasak W.R., Farrar G.E., Broyles J.E., and Welch J.E. Inhibition of neural and neuroendocrine activity by alpha-interferon: neuroendocrine, electrophysiological, and biochemical studies in the rat. Brain Behav. Immun. 8 (1994) 37-56
49. Sato T., Suzuki E., Yokoyama M., Semba J., Watanabe S., and Miyaoka H. Chronic intraperitoneal injection of interferon-alpha reduces serotonin levels in various regions of rat brain, but does not change levels of serotonin transporter mRNA, nitrite or nitrate. Psychiatry Clin. Neurosci. 60 (2006) 499-506
50. Schaefer M., Schwaiger M., Pich M., Lieb K., and Heinz A. Neurotransmitter changes by interferon-alpha and therapeutic implications. Pharmacopsychiatry 36 (2003) S203-S206
51. Schramm T.M., Lawford B.R., Macdonald G.A., and Cooksley W.G. Sertraline treatment of interferon-alfa-induced depressive disorder. Med. J. Aust. 173 (2000) 359-361
52. Sheridan J.F., Stark J.L., Avitsur R., and Padgett D.A. Social disruption, immunity, and susceptibility to viral infection. Role of glucocorticoid insensitivity and NGF. Ann. N.Y. Acad. Sci. 917 (2000) 894-905
53. Shimizu H., Ohtani K., Sato N., Nagamine T., and Mori M. Increase in serum interleukin-6, plasma ACTH and serum cortisol levels after systemic interferon-alpha administration. Endocr. J. 42 (1995) 551-556
54. Shuto H., Kataoka Y., Horikawa T., Fujihara N., and Oishi R. Repeated interferon-alpha administration inhibits dopaminergic neural activity in the mouse brain. Brain Res. 747 (1997) 348-351
55. Sluzewska A. Indicators of immune activation in depressed patients. Adv. Exp. Med. Biol. 461 (1999) 59-73
56. Turecki G., Briere R., Dewar K., Antonetti T., Lesage A.D., Seguin M., et al. Prediction of level of serotonin 2A receptor binding by serotonin receptor 2A genetic variation in postmortem brain samples from subjects who did or did not commit suicide. Am. J. Psychiatr. 156 (1999) 1456-1458
57. Valentine A.D., and Meyers C.A. Neurobehavioral effects of interferon therapy. Curr. Psychiatry Rep. 7 (2005) 391-395
58. Wichers M.C., and Maes M. The role of indoleamine 2,3-dioxygenase (IDO) in the pathophysiology of interferon-alpha-induced depression. J. Psychiatry Neurosci. 29 (2004) 11-17
59. Yirmiya R., Weidenfeld J., Pollak Y., Morag M., Morag A., Avitsur R., et al. Cytokines, "depression due to a general medical condition," and antidepressant drugs. Adv. Exp. Med. Biol. 461 (1999) 283-316